ClinicalTrials.gg
TerminatedNCT00811993Updated Nov 2, 2016

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors

A Phase 1 interventional study of RG1507 and RO1507 in Neoplasms, sponsored by Hoffmann-La Roche. Terminated at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-02.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
104
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate the safety and tolerability of R1507 in combination with 12 distinct standard chemotherapy drug regimens and an additional R1507 monotherapy arm in patients with advanced malignant neoplasms.The 12 regimens will be tested in parallel. There are 3 subsets of patients who are eligible for the study: untreated, treated and requiring further treatment, or treated and failed and for whom adding R1507 represents a suitable treatment for their disease. All regimens will first test doses of R1507 which are less than the maximally administered dose, and if tolerated, the dose will be escalated in subsequent patients. The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.

02

Conditions studied

  • Neoplasms

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 104 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, >=18 years of age;
  • malignant neoplasms;
  • failed prior standard curative therapy;
  • performance Status of 0 or 1;
  • adequate bone marrow, hepatic and renal function;
  • greater than 8 weeks.

Exclusion criteria

Exclusion Criteria:

  • chemotherapy within 2 weeks of start of therapy;
  • prior irradiation within 4 weeks prior to start of therapy;
  • prior treatment with agents targeting IGF-IR inhibition, or other agents;
  • major surgery or significant traumatic injury within 2 weeks prior to study start;
  • patients receiving concurrent antibody or immunotherapy;
  • other exclusion criteria are related to specific treatment regimens.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
104 participants (actual)

Study arms

  • Experimental
    1

    Drug: RG1507 · Drug: erlotinib [Tarceva] · Drug: gemcitabine

  • Experimental
    10

    Drug: RG1507 · Drug: temozolomide

  • Experimental
    11

    Drug: RG1507 · Drug: bevacizumab [Avastin] · Drug: docetaxel

  • Experimental
    12

    Drug: RG1507 · Drug: pemetrexel

  • Experimental
    13

    Drug: RO1507

  • Experimental
    2

    Drug: RG1507 · Drug: bevacizumab [Avastin] · Drug: paclitaxel

  • Experimental
    3

    Drug: RG1507 · Drug: carboplatin · Drug: etoposide

  • Experimental
    4

    Drug: RG1507 · Drug: bevacizumab [Avastin] · Drug: mFOLFOX6

  • Experimental
    5

    Drug: RG1507 · Drug: capecitabine [Xeloda] · Drug: trastuzumab [Herceptin]

  • Experimental
    6

    Drug: RG1507 · Drug: sorafenib

  • Experimental
    7

    Drug: RG1507 · Drug: bevacizumab [Avastin] · Drug: erlotinib [Tarceva]

  • Experimental
    8

    Drug: RG1507 · Drug: cetuximab · Drug: irinotecan

  • Experimental
    9

    Drug: RG1507 · Drug: bevacizumab [Avastin] · Drug: carboplatin · Drug: paclitaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse events, laboratory parameters, vital signs

    Time frame: Throughout study

Secondary outcomes

  1. Trough levels of R1507

    Time frame: Throughout study

07

Study locations

8 sites
  • Tucson, Arizona 85724, United States
  • San Francisco, California 94115, United States
  • Santa Monica, California 90025, United States
  • Washington, District of Columbia 20007, United States
  • Chicago, Illinois 60637, United States
  • Rochester, Minnesota 55905, United States
  • Chapel Hill, North Carolina 27514, United States
  • Houston, Texas 77030, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2008
First posted
Dec 19, 2008
Start
Feb 2009
Primary completionActual
Dec 2012
CompletionActual
Dec 2012
Last update
Nov 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00811993
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 19, 2008
Start date
Feb 2009
Primary completion
Dec 2012
Completion
Dec 2012
Last update
Nov 2, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teprotumumab

Start the discussion